Clicky

Intellia Therapeutics Inc(38I)

Description: Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.


Keywords: Biotechnology Life Sciences Biology Immune System Stem Cell Acute Myeloid Leukemia Enzymes Genetic Engineering Treatment Of Acute Myeloid Leukemia Hereditary Angioedema Antitrypsin Deficiency CRISPR Genome Editing Hemophilia A Treatment Of Hemophilia Sickle Cell Disease Transthyretin Cas9 Hemophilia B Ocular Disease Transthyretin Amyloidosis Intellia Therapeutics

Home Page: www.intelliatx.com

40 Erie Street
Cambridge, MA 02139
United States
Phone: 857 285 6200


Officers

Name Title
Dr. John M. Leonard M.D. Pres, CEO & Director
Mr. Glenn G. Goddard CPA Exec. VP, CFO & Treasurer
Dr. Laura Sepp-Lorenzino Ph.D. Exec. VP & Chief Scientific Officer
Mr. James E. Basta Esq., J.D. Exec. VP, Gen. Counsel & Corp. Sec.
Dr. David Lebwohl M.D. Exec. VP & Chief Medical Officer
Mr. Nessan Bermingham Ph.D. Founder & Member of Scientific Advisor Board
Dr. Rachel E. Haurwitz Ph.D. Co-Founder
Dr. Andrew May Founder and Member of Scientific Advisor Board
Dr. Jennifer A. Doudna Ph.D. Founder & Member of Scientific Advisor Board
Dr. Derrick J. Rossi Ph.D. Founder & Member of Scientific Advisor Board

Exchange: F

Country: DE

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.0075
Price-to-Sales TTM: 58.1521
IPO Date:
Fiscal Year End: December
Full Time Employees: 485
Back to stocks